Samira Kaissi

🎉 Join INTEGRA Biosciences at the Biosciences Institute in University College Cork 🎉 💡 Discover the brilliance of PIPETBOY Genius – the ultimate pipetting assistant for precision and comfort. #IntegraBiosciences #LabInnovation #PipettingRevolution #LifeSciences #LaboratoryAutomation #SerologicalPipet #ElectronicPipettes #ManualPipettes #ManualPipetting #MINI96 #ProductivePipetting

37

1 Comment

🎉 Join INTEGRA Biosciences at the Biosciences Institute in University College Cork 🎉 💡 Discover the brilliance of PIPETBOY Genius – the ultimate pipetting assistant for precision and comfort. #IntegraBiosciences #LabInnovation #PipettingRevolution #LifeSciences #LaboratoryAutomation #SerologicalPipet #ElectronicPipettes #ManualPipettes #ManualPipetting #MINI96 #ProductivePipetting

22

Tackling Tick Troubles: Insights and Impacts of Lyme Disease in Ireland The rising prevalence of tick-borne infections (TBIs) is a growing concern in Ireland. A recent study investigated the types of TBIs, their symptoms, and the effectiveness of combination antibiotic treatments in a large patient cohort. Among 301 patients, 46.51% tested positive for TBIs, with the majority infected by Borrelia. The study found that combination antibiotics significantly reduced pain and neurological symptoms, demonstrating good patient tolerance and effectiveness in alleviating TBI symptoms. Further research focused on clinical biomarkers in 110 patients before and after antibiotic treatment. Initially, patients had low counts of several immune cells, including CD3%, CD3+ cells, and CD4+ helper cells. Post-treatment, most of these counts improved, highlighting the potential of standard clinical markers in assisting TBI diagnosis. However, CD8+ counts showed no notable progress, indicating the need for more research on immune responses to TBIs. Pain is a common and debilitating symptom of TBIs, particularly in patients with post-treatment Lyme disease syndrome (PTLDS). An Irish hospital study explored the relationship between pain and biomarkers in TBI patients before and after antibiotic treatment. Pain ratings significantly decreased post-treatment, suggesting persistent infections responsive to antibiotics. Although some biomarkers were correlated with pain ratings, they did not directly predict pain changes. This finding underscores the importance of appropriate antibiotic treatment and the human rights implications of withholding pain relief. Beyond the health impacts, TBIs also impose a significant economic burden. A study estimated the prevalence and cost of Chronic Lyme Disease (CLD) in Ireland, revealing an annual cost of 40,699 EUR per patient and a national total of 305.24 million EUR. Timely detection and treatment of Lyme disease can reduce these costs and prevent long-term complications. The study called for enhanced training for general practitioners and increased awareness among policymakers about the impact of Lyme disease, comparing its prevalence to that of the COVID-19 pandemic. By synthesizing these studies, it is evident that Lyme disease and other TBIs pose significant health and economic challenges in Ireland. Improved diagnostic markers, effective treatments, and comprehensive healthcare policies are crucial in managing and mitigating the impact of these infections. #tickplex www.tezted.com @tez_ted See also the video at https://lnkd.in/dFvQ7DdV https://lnkd.in/daC3VHb6 https://lnkd.in/dhWfSQtv https://lnkd.in/dsxu_3fX

5

In March 2024, Applied Biopharm Consulting received funding from Local Enterprise Office Cork North and West to conduct a feasibility study to evaluate the engineering of viral capsids and related molecules. This research used artificial intelligence combined with advanced computational tools to develop and validate Applied Dock™ technology. Looking ahead to 2025, our ongoing R&D efforts will focus on experimentally evaluating the integration of novel high-affinity binding motifs targeting a specific muscle receptor. These studies aim to assess AAV muscle transduction efficiency and compare these results with other myotropic AAVs, with the ultimate goal of developing novel gene therapies and enhancing muscle functionality. #biotech #genetherapy #lifesciences #innovation #aavresearch

16

6 Comments

An interesting strategy.

10

You can still register for this webinar, demonstrating the Quantum-Aided Drug Design (#QuADD) platform.

10

On Father's Day this year, I presented our work on NaNots at the superb Longevity Summit Dublin conference. Sticking around so I can enjoy and support friends and family is a big reason why I'm interested in longevity science. NaNots, the new class of medicine our company is developing, will have their initial application in FDA-recognized conditions like cancer and sepsis, but our scientists believe that the NaNot platform also has strong utility against core mechanisms of aging, some of which I describe in this talk. Enjoy! #nanotech #medicine #innovation #longevity

28

4 Comments

ARIZ is very pleased to announce the first phase in a collaboration with the UK's Medical Research Council's Nucleic Acid Therapeutics Accelerator (NATA) to fund early stage development of nucleic acid therapy (NAT) drug candidates for novel gene targets with strong genetic associations to leading cancers. The collaboration combines NATA’s expertise in NAT design and ARIZ’s RNAi compounds, which are being developed to treat a range of cancers. https://lnkd.in/ghR5iFi2 Nick Lench Sritama Bose, PhD Ravi Kiron SIC Venture Studio Jim Burden

85

12 Comments

Thrilled to announce my recent feature in a Labiotech.eu article delving into some of the details of small-molecule drugs. At EQUULUS Therapeutics, we're particularly focused on developing small-molecule drugs to treat CNS disorders, in particular, addiction disorders, leveraging their ability to penetrate the blood-brain barrier. With our lead asset, EQL-101, a non-hallucinogenic and non-cardiotoxic ibogaine analog, we aim to provide a safe and powerful alternative to traditional addiction therapies. Additionally, the rise of #artificialintelligence (AI) is transforming small-molecule drug discovery, accelerating the process and increasing innovation. With AI-driven advancements, the small-molecule drug discovery market is projected to reach new heights, ensuring its continued prominence in disease treatment.  Check out the full feature for more on the topic and check out EQUULUS Therapeutics and please click on +Follow to stay informed of our progress. #Biotech #HealthcareInnovation #SmallMolecules #DrugDiscovery #Neuroscience, #Addiction

16

1 Comment

🧬 Exciting Advances in Microbiome Data Science 🧬 At the recent Microbiome Data Webinar, leading researchers shared groundbreaking insights into the microbiome and the power of multi-omics and machine learning. Here are some key highlights: 🔍 Colin Hill (APC Microbiome Ireland) – Why the virome is a critical piece in understanding microbial ecosystems. 🤖 Jaejin Lee (Iowa State University) – Machine learning can support decision-making for tackling cyanobacterial blooms (CyanoHABs) but remember, “garbage in, garbage out”! 📊 Tal Korem (DEBIAS-M) – Overcoming challenges in cross-study microbiome predictions with advanced batch correction methods. Check it out! 🏡 Cedo (Nimble Science) – Home kits and multi-omics sampling are transforming microbiome research, making data collection easier and more accurate. 🍽️ Niccolo – The fascinating overlap between the food microbiome and human microbiome, with insights from 2,500 food metagenomes. 💡 Daniel (Knight Lab) – Large-scale studies are unlocking patterns in microbiome data using Qiita and Greengenes2. 💬 These innovations highlight how data science is accelerating microbiome research. What recent advancements in microbiome science have caught your eye? #microbiome #bioinformatics #dataanalysis #multiomics #machinelearning #citizenscience

8

At #sitryx we understand that an important part of the foundation to a highly functional #team is how it communicates not just with in itself but within the wider organisation to drive our #drugdiscovery forward to develop novel #Therapeutics to address #patient need. A wonderfully engaged session with the #biology team exploring what they understood about #Emotionalintelligence and how it can be used to bring more #effective #communication with enhanced #engagement and positive reaction to challenges.

30

Here is an interesting article about the struggle to translate CRISPR technology into clinical practice. I’m eager to hear your opinion. https://lnkd.in/dumsXDhH In the evolving biotechnology landscape, introducing powerful innovations such as CRISPR-based therapies, like Vertex’s Casgevy, marks a significant step forward in treating complex diseases. However, technological breakthroughs do not always guarantee immediate success, no matter how advanced. The journey from innovation to widespread societal integration is often fraught with challenges, as the complexity of the technology can create hurdles for both market adoption and patient access. True success in this field hinges on the urgent development of products that are not just technically simple and operationally efficient, but also user-friendly and budget reasonable for the healthcare sector. The need for simplicity here is not a compromise on innovation, but rather a focus on accessibility, cost-effectiveness, and scalability. Moreover, the societal context is a key determinant of the success of any new technology. Without adequate education and awareness, even the most revolutionary treatments may struggle to gain traction in clinical practice. The pharmaceutical industry's role is not limited to pushing the boundaries of scientific possibility. It also includes the responsibility to ensure that these innovations are not just technically advanced but also culturally and operationally integrated into the healthcare system. This involves fostering technological progress and contributing to the education of healthcare professionals and the broader society about the potential, limitations, and applications of new treatments. Ultimately, the future of biotech is not solely in the hands of those who create the technology but in how well we, as a society, are prepared to adopt and understand it. The path to profitability and widespread use of technologies like CRISPR depends on technical achievements and the alignment of industry, healthcare systems, and society.

12

I’m hugely excited to announce that I’ve joined Swan Neck Bio as Director of Business Development. Over many years, I’ve experienced the excitement - and impact - of deep-tech, science-based partnerships and seen the growth of the biosolutions field. I’m inspired to join a team that is making huge strides in supporting organizations using fermentation technologies to change our collective approach to planetary health. Swan Neck Bio has observed two often overlooked challenges in biomanufacturing: scaling early-stage production and addressing the risk/cost of the seed train. Our team and technology enables us to: * Mitigate the risks of scaling fermentations, sample production, and prototyping at scale while avoiding the high costs of pilot plants * Outsource our partner’s seed train and increase bioreactor uptime by 20% and reduce QC failure by up to 30% If your team is facing challenges within fermentation, I’d love to listen to you.  My activity demands listening to stakeholders across the deeptech space such as start-ups, biosolution manufacturers, venture capital teams and university accelerators. You can find further detail on Swan Neck Bio in the link in the comments - or even better - connect with me here on Linkedin 🙏. Troels Prahl Mark Emil Hermansen Michela Winters, PhD Arca (Ardja) Yilmaz Toby Richardson #biosolutions #biomanufacturing #planetaryhealth #foodtech #alternativeprotein #healthierplanet #food #health #nutrition

62

12 Comments

Big moves are happening in the world of Biotech manufacturing! WuXi Biologics' sell its state-of-the-art vaccine production facility in Dundalk, Ireland, to Merck for €500 million reflects the ongoing evolution of the global biopharma landscape. #CDMO #Drugmanufacturing #biologics

9

This is a great theme for the analyst report, highlighting the great potential of scalable regenerative cell therapies. A recommended read.

18

An #exciting #hybrid #event coming to you from Genomes.io in partnership with Opportunity North East Limited #BioHub and BlockStart Scotland! 🌟 Join #DeSci Scotland on the 13th of June 2024 at Opportunity North East Limited #BioHub or online! What is #DeSci #Scotland? 🤔 #DeSci Scotland aims to dive into the world of data science to explore the latest trends and technologies with academic and industry experts. This event is focusing on the concept of Decentralised Science (DeSci), a narrative using blockchain technology to ensure that healthcare data is queried in such a way that it benefits all stakeholders involved! This event is targeting #datascientists, #molecularbiologists, #geneticists and anyone curious about the field! More details and the registration link can be found in the #attached post! 🤩 (Please not that this link is for anyone planning to join remotely). Please get in touch if you would like to attend in-person! 😊 #genomics #genomicdata #datascience #genetics #humangenomics #biotechnology ONE Life Sciences

17

2 Comments

"iPSC technology has developed swiftly since 2006, since iPSCs have demonstrated their usefulness in drug development and discovery, disease modeling, toxicology testing, cell therapy, gene therapy, disease modelling, personalized medicine, cultured meat production, and beyond." Good overview of the big players making an impact in this space #services #ips #drugdiscovery #cro #toxicity ://https://lnkd.in/gk5_A2rE

1